Drug Discovery and Development for Reward Disorders: Views from Government

Animal and Translational Models for CNS Drug Discovery

Volumn , Issue , 2008, Pages 23-40

  McCann, David J ^a   Acri, Jane B ^a   Vocci, Frank J ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884836893     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373861-5.00022-9     Document Type: Chapter

References (43)

1. R.E. Johnson, J.H. Jaffe and P.J. Fudala (1992) A controlled trial of buprenorphine treatment for opioid dependence. JAMA 267(20), 2750-2755.
2. W. Ling, C. Charuvastra, J.F. Collins, S. Batki, L.S. Brown Jr., P. Kintaudi, et al. (1998) Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 93(4), 475-486.
3. P.J. Fudala, E. Yu, W. Macfadden, C. Boardman and C.N. Chiang (1998) Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 50(1), 1-8.
4. J. Mendelson, R.T. Jones, S. Welm, M. Baggott, I. Fernandez, A.K. Melby, et al. (1999) Buprenorphine and naloxone combinations: The effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology (Berl) 141(1), 37-46.
5. D.S. Harris, R.T. Jones, S. Welm, R.A. Upton, E. Lin and J. Mendelson (2000) Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 61(1), 85-94.
6. P.J. Fudala, T.P. Bridge, S. Herbert, W.O. Williford, C.N. Chiang, K. Jones, et al. (2003) Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New Engl J Med 349(10), 949-958.
7. S.D. Comer, M.A. Sullivan, E. Yu, J.L. Rothenberg, H.D. Kleber, K. Kampman, et al. (2006) Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Arch Gen Psychiatry 63(2), 210-218.
8. F. Vocci and W. Ling (2005) Medications development: Successes and challenges. Pharmacol Ther 108(1), 94-108.
9. J. Tiihonen, K. Kuoppasalmi, J. Fohr, P. Tuomola, O. Kuikanmaki, H. Vorma, et al. (2007) A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 164(1), 160-162.
10. Elkashef, A.M., Rawson, R.A., Smith, E., Anderson, A., Kahn, R., Pierce, V., et al. (2006). Bupropion for the treatment of methamphetamine dependence. Presented at the College on Problems of Drug Dependence Meeting, Scottsdale, Arizona.
11. F.B. Le and S.R. Goldberg (2005) Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 312(3), 875-883.
12. S.R. Vorel, C.R. Ashby Jr., M. Paul, X. Liu, R. Hayes, J.J. Hagan, et al. (2002) Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci 22(21), 9595-9603.
13. C. Heidbreder (2005) Novel pharmacotherapeutic targets for the management of drug addiction. Eur J Pharmacol 526(1–3), 101-112.
14. H. Rollema, L.K. Chambers, J.W. Coe, J. Glowa, R.S. Hurst, L.A. Lebel, et al. (2007) Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52(3), 985-994.
15. N.K. Mello, M.P. Bree and J.H. Mendelson (1983) Comparison of buprenorphine and methadone effects on opiate self-administration in primates. J Pharmacol Exp Ther 225(2), 378-386.
16. J.A. DiMasi, R.W. Hansen and H.G. Grabowski (2003) The price of innovation: New estimates of drug development costs. J Health Econ 22(2), 151-185.
17. H. Rollema, L.K. Chambers, J.W. Coe, J. Glowa, R.S. Hurst, L.A. Lebel, et al. (2007) Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52(3), 985-994.
18. Y. Shaham, U. Shalev, L. Lu, W.H. De and J. Stewart (2003) The reinstatement model of drug relapse: History, methodology and major findings. Psychopharmacology (Berl) 168(1–2), 3-20.
19. B. Boutrel, P.J. Kenny, S.E. Specio, R. Martin-Fardon, A. Markou, G.F. Koob, et al. (2005) Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci USA 102(52), 19168-19173.
20. L. Yao, K. McFarland, P. Fan, Z. Jiang, T. Ueda and I. Diamond (2006) Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats. Proc Natl Acad Sci USA 103(20), 7877-7882.
21. P.B. Dews (1958) Studies on behavior. IV. Stimulant actions of methamphetamine. J Pharmacol Exp Ther 122(1), 137-147.
22. P.M. Beardsley, J.L. Howard, K.L. Shelton and F.I. Carroll (2005) Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl) 183(1), 118-126.
23. P.B. Dews (1955) Studies on behavior. I. Differential sensitivity to pentobarbital of pecking performance in pigeons depending on the schedule of reward. J Pharmacol Exp Ther 113(4), 393-401.
24. L.J. Lesko (2007) Paving the critical path: How can clinical pharmacology help achieve the vision? Clin Pharmacol Ther 81(2), 170-177.
25. M.W. Fischman and R.W. Foltin (1992) A laboratory model for evaluating potential treatment medications in humans. NIDA Res Monogr 119 165-169.
26. R. Sinha, T. Fuse, L.R. Aubin and S.S. O’Malley (2000) Psychological stress, drug-related cues and cocaine craving. Psychopharmacology (Berl) 152(2), 140-148.
27. N.K. Mello, M.P. Bree and J.H. Mendelson (1983) Comparison of buprenorphine and methadone effects on opiate self-administration in primates. J Pharmacol Exp Ther 225(2), 378-386.
28. M.K. Greenwald, K.J. Schuh, J.A. Hopper, C.R. Schuster and C.E. Johanson (2002) Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology (Berl) 160(4), 344-352.
29. D.R. Britton, P. Curzon, R.G. Mackenzie, J.W. Kebabian, J.E. Williams and D. Kerkman (1991) Evidence for involvement of both D1 and D2 receptors in maintaining cocaine self-administration. Pharmacol Biochem Behav 39(4), 911-915.
30. W.A. Corrigall and K.M. Coen (1991) Cocaine self-administration is increased by both D1 and D2 dopamine antagonists. Pharmacol Biochem Behav 39(3), 799-802.
31. J. Bergman, J.B. Kamien and R.D. Spealman (1990) Antagonism of cocaine self-administration by selective dopamine D(1) and D(2) antagonists. Behav Pharmacol 1(4), 355-363.
32. R.D. Spealman (1990) Antagonism of behavioral effects of cocaine by selective dopamine receptor blockers. Psychopharmacology (Berl) 101(1), 142-145.
33. M.K. Romach, P. Glue, K. Kampman, H.L. Kaplan, G.R. Somer, S. Poole, et al. (1999) Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). Arch Gen Psychiatry 56(12), 1101-1106.
34. M. Haney, A.S. Ward, R.W. Foltin and M.W. Fischman (2001) Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacology (Berl) 155(4), 330-337.
35. E. Nann-Vernotica, E.C. Donny, G.E. Bigelow and S.L. Walsh (2001) Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine. Psychopharmacology (Berl) 155(4), 338-347.
36. E.F. Cance-Katz, T.A. Kosten and T.R. Kosten (2001) Going from the bedside back to the bench with ecopipam: A new strategy for cocaine pharmacotherapy development. Psychopharmacology (Berl) 155(4), 327-329.
37. M.S. Cousins, D.C. Roberts and W.H. de (2002) GABA(B) receptor agonists for the treatment of drug addiction: A review of recent findings. Drug Alcohol Depend 65(3), 209-220.
38. D.C. Roberts (2005) Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction. Physiol Behav 86(1–2), 18-20.
39. D.C. Roberts, M.M. Andrews and G.J. Vickers (1996) Baclofen attenuates the reinforcing effects of cocaine in rats. Neuropsychopharmacology 15(4), 417-423.
40. C.P. Di and B.J. Everitt (2003) The GABA(B) receptor agonist baclofen attenuates cocaine- and heroin-seeking behavior by rats. Neuropsychopharmacology 28(3), 510-518.
41. U.C. Campbell, S.T. Lac and M.E. Carroll (1999) Effects of baclofen on maintenance and reinstatement of intravenous cocaine self-administration in rats. Psychopharmacology (Berl) 143(2), 209-214.
42. M. Haney, C.L. Hart and R.W. Foltin (2006) Effects of baclofen on cocaine self-administration: Opioid- and nonopioid-dependent volunteers. Neuropsychopharmacology 31(8), 1814-1821.
43. S. Shoptaw, X. Yang, E.J. Rotheram-Fuller, Y.C. Hsieh, P.C. Kintaudi, V.C. Charuvastra, et al. (2003) Randomized placebo-controlled trial of baclofen for cocaine dependence: Preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 64(12), 1440-1448.